-transparent.png){kind=logo}
Fas ligand (FasL) belongs to the TNF superfamily. It is induced in activated lymphocytes and eliminates Fas-positive lymphocytes, resulting in the down-regulation of immune responses. FasL has also been detected in tissues other than lymphoid cells. We investigated the expression and function of FasL on human colon cancer cells. FasL mRNA was detected by RT-PCR in all six colon cancer cell lines tested and was not found on fibroblasts. FasL protein was detected in DLD-1, LoVo, HCT-116 and RPMI 4788 cells by immunohistochemical staining. DLD-1, LoVo and WiDr were cytotoxic against mouse T lymphoma cells which were transfected with human Fas receptor cDNA. The cytotoxicity was significantly enhanced by phorbol 12-myristate 13-acetate (PMA) and ionomycin. Our data suggest that the FasL expressed in human colon cancer cells may be regulated by endogenous factors in the microenvironment of the host and facilitates the escape from the host immune system.
E X Ding, and
A Hizuta, and
Y Morimoto, and
T Tanida, and
T Hongo, and
T Ishii, and
T Yamano, and
T Fujiwara, and
H Iwagaki, and
N Tanaka
March 1996,
European journal of immunology,
E X Ding, and
A Hizuta, and
Y Morimoto, and
T Tanida, and
T Hongo, and
T Ishii, and
T Yamano, and
T Fujiwara, and
H Iwagaki, and
N Tanaka
March 1997,
Cancer research,
E X Ding, and
A Hizuta, and
Y Morimoto, and
T Tanida, and
T Hongo, and
T Ishii, and
T Yamano, and
T Fujiwara, and
H Iwagaki, and
N Tanaka
January 2001,
International journal of oncology,
E X Ding, and
A Hizuta, and
Y Morimoto, and
T Tanida, and
T Hongo, and
T Ishii, and
T Yamano, and
T Fujiwara, and
H Iwagaki, and
N Tanaka
January 1999,
Cancer research,
E X Ding, and
A Hizuta, and
Y Morimoto, and
T Tanida, and
T Hongo, and
T Ishii, and
T Yamano, and
T Fujiwara, and
H Iwagaki, and
N Tanaka
September 1996,
The Journal of experimental medicine,
E X Ding, and
A Hizuta, and
Y Morimoto, and
T Tanida, and
T Hongo, and
T Ishii, and
T Yamano, and
T Fujiwara, and
H Iwagaki, and
N Tanaka
September 2003,
Cancer research,
E X Ding, and
A Hizuta, and
Y Morimoto, and
T Tanida, and
T Hongo, and
T Ishii, and
T Yamano, and
T Fujiwara, and
H Iwagaki, and
N Tanaka
October 2007,
Stem cells (Dayton, Ohio),
E X Ding, and
A Hizuta, and
Y Morimoto, and
T Tanida, and
T Hongo, and
T Ishii, and
T Yamano, and
T Fujiwara, and
H Iwagaki, and
N Tanaka
December 1999,
Hepatology (Baltimore, Md.),
E X Ding, and
A Hizuta, and
Y Morimoto, and
T Tanida, and
T Hongo, and
T Ishii, and
T Yamano, and
T Fujiwara, and
H Iwagaki, and
N Tanaka
April 1998,
Cancer research,
E X Ding, and
A Hizuta, and
Y Morimoto, and
T Tanida, and
T Hongo, and
T Ishii, and
T Yamano, and
T Fujiwara, and
H Iwagaki, and
N Tanaka
February 1998,
Bulletin du cancer,
